Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H11ClN2O.ClH |
| Molecular Weight | 235.11 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.ClC1=NC=C(OC[C@H]2CCN2)C=C1
InChI
InChIKey=GYVARJONEFSAJB-OGFXRTJISA-N
InChI=1S/C9H11ClN2O.ClH/c10-9-2-1-8(5-12-9)13-6-7-3-4-11-7;/h1-2,5,7,11H,3-4,6H2;1H/t7-;/m1./s1
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C9H11ClN2O |
| Molecular Weight | 198.649 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine] is a potent cholinergic neuronal nicotinic acetylcholine receptor (nAChR) ligand with analgesic properties. ABT-594 binds alpha-4/ beta-2 neuronal nAChRs acting as an agonist. ABT-594 is studying for the treatment of diabetic peripheral neuropathic pain.
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19632048 |
300 μg 2 times / day multiple, oral dose: 300 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
TEBANICLINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.73 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19632048 |
300 μg 2 times / day multiple, oral dose: 300 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
TEBANICLINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
22.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19632048 |
300 μg 2 times / day multiple, oral dose: 300 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
TEBANICLINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
25 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19632048 |
300 μg 2 times / day multiple, oral dose: 300 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
TEBANICLINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization. | 1998 May |
|
| Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat. | 2007 Feb |
|
| Morphine and ABT-594 (a nicotinic acetylcholine agonist) exert centrally mediated antinociception in the rat cyclophosphamide cystitis model of visceral pain. | 2008 Feb |
|
| Preparation and characterization of N-(3-pyridinyl) spirocyclic diamines as ligands for nicotinic acetylcholine receptors. | 2009 Mar 15 |
|
| Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent pain. | 2010 Apr |
Patents
Sample Use Guides
Efficacy, safety and pharmacokinetics of ABT-594 in subjects with painful diabetic polyneuropathy were evaluated in a randomized, double-blind, placebo-controlled, parallel-group, multi-centre, 7-week Phase 2 study: subjects were approximately equally divided into four groups to receive BID regimens of placebo or 150, 225 and 300 ug of ABT-594.
ABT-894 was evaluated in 2 separate randomized, double-blind, multicenter, placebo-controlled clinical trials in patients with diabetic peripheral neuropathic pain. Study 1 (280 patients randomized) tested 1, 2, and 4 mg ABT-894 twice daily compared with placebo and 60 mg duloxetine once per day over 8 weeks of treatment. Study 2 (124 patients randomized) tested 6 mg ABT-894 twice daily vs placebo for 8 weeks.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:58:14 GMT 2023
by
admin
on
Sat Dec 16 08:58:14 GMT 2023
|
| Record UNII |
48U2WUT775
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
72193963
Created by
admin on Sat Dec 16 08:58:14 GMT 2023 , Edited by admin on Sat Dec 16 08:58:14 GMT 2023
|
PRIMARY | |||
|
203564-54-9
Created by
admin on Sat Dec 16 08:58:14 GMT 2023 , Edited by admin on Sat Dec 16 08:58:14 GMT 2023
|
PRIMARY | |||
|
m10497
Created by
admin on Sat Dec 16 08:58:14 GMT 2023 , Edited by admin on Sat Dec 16 08:58:14 GMT 2023
|
PRIMARY | Merck Index | ||
|
48U2WUT775
Created by
admin on Sat Dec 16 08:58:14 GMT 2023 , Edited by admin on Sat Dec 16 08:58:14 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
